ChiCTR2200066934 版本V1.0 版本创建时间2022/12/21 16:32:03 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2200066934 

最近更新日期:

Date of Last Refreshed on:

2022-12-21 16:31:58 

注册时间:

Date of Registration:

2022-12-21 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

前列腺癌术后尿控功能评估及盆底肌锻炼疗效分析

Public title:

Evaluation of urinary function and the effect of pelvic floor muscle exercise after radical prostatectomy

注册题目简写:

English Acronym:

研究课题的正式科学名称:

前列腺癌术后尿控功能评估及盆底肌锻炼疗效分析

Scientific title:

Evaluation of urinary function and the effect of pelvic floor muscle exercise after radical prostatectomy

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

余燕岚 

研究负责人:

丁国庆 

Applicant:

Yanlan Yu 

Study leader:

Guoqing Ding 

申请注册联系人电话:

Applicant telephone:

+86 13588170787

研究负责人电话:

Study leader's
telephone:

+86 13867438309

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

yanlanyu@yeah.net

研究负责人电子邮件:

Study leader's E-mail:

3196014@zju.edu.cn

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

浙江省杭州市庆春东路3号

研究负责人通讯地址:

浙江省杭州市庆春东路3号

Applicant address:

No.3, East Qingchun Road, Hangzhou, Zhejiang Province

Study leader's address:

No.3, East Qingchun Road, Hangzhou, Zhejiang Province

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

浙江大学医学院附属邵逸夫医院

Applicant's institution:

Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University

研究负责人所在单位:

浙江大学医学院附属邵逸夫医院

Affiliation of the Leader:

Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

邵逸夫医院伦审2022研第0208号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

浙江大学医学院附属邵逸夫医院医学伦理委员会

Name of the ethic committee:

Medical ethics committee of Sir Run Run Shaw Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2022-07-08 00:00:00

伦理委员会联系人:

金烨成

Contact Name of the ethic committee:

Jin Yecheng

伦理委员会联系地址:

浙江省杭州市庆春东路3号邵逸夫医院4号楼9楼908办公室

Contact Address of the ethic committee:

Office 908, 9/F, Building 4, Sir Run Run Shaw Hospital, No.3 Qingchun East Road, Hangzhou, Zhejiang, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 571 86006643

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

浙江大学医学院附属邵逸夫医院

Primary sponsor:

Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University

研究实施负责(组长)单位地址:

浙江省杭州市庆春东路3号

Primary sponsor's address:

No.3, East Qingchun Road, Hangzhou, Zhejiang Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中华人民共和国

省(直辖市):

浙江省

市(区县):

杭州市

Country:

China

Province:

Zhejiang Province

City:

Hangzhou

单位(医院):

浙江大学医学院附属邵逸夫医院

具体地址:

浙江省杭州市庆春东路3号

Institution
hospital:

Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University

Address:

No.3, East Qingchun Road, Hangzhou, Zhejiang Province

经费或物资来源:

浙江省科技厅重点研发项目(2021C03062)

Source(s) of funding:

Key R&D Program of Zhejiang province (2021C03062)

研究疾病:

尿失禁  

Target disease:

incontinence

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

I期临床试验 

Study phase:

1

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

本研究拟客观评估前列腺癌术后控尿功能,利用盆底超声、神经电生理检测等评估手段,评估各种因素与控尿功能相关性,制定规范化参数标准;评估不同术式、入路(经腹、腹膜后、经会阴、单孔等)对控尿的影响;研究干预因素(盆底肌训练)等对术后后尿控恢复的作用。  

Objectives of Study:

The research is designed to objectively assess urinary function after radical prostatectomy by using pelvic floor ultrasound, neurophysiological testing and other assessment tools to evaluate the correlations between various factors and urinary function and to establish standardized parameter criteria; to assess the effects of different surgical procedures and approaches (transabdominal, retroperitoneal, transperineal, single-port, etc.) on urinary function; and to study the role of intervention factor(pelvic floor muscle training) on the recovery of urinary function after surgery.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

①前列腺穿刺病理检查证实,且行MRI或CT扫描检查确诊,排除术前已转移者及手术禁忌者;②拟行机器人辅助前列腺癌根治术;③ 术后出现尿失禁者;④术前无盆底肌锻炼知识背景;⑤ 经研究者说明后,愿意参加本研究。

Inclusion criteria

(1)Patients with prostate cancer confirmed by prostate puncture pathology and MRI or CT scan, excluding those with preoperative metastases and surgical contraindications; (2) Patients who were intended to have robotic-assisted radical prostatectomy; (3) Patients with postoperative urinary incontinence; (4) Patients without preoperative knowledge of pelvic floor muscle exercise; (5) Patients who were willing to participate in the research after the investigator's explanation.

排除标准:

①患者有严重的心功能、肺功能或凝血功能障碍未得到纠正,存在多发骨转移或其他远处转移;② 术前存在严重膀胱功能障碍患者;③既往有盆腔手术史,盆腔放疗史的患者;④沟通交流障碍者;⑤ 研究者认为不宜参加研究的其他情况。

Exclusion criteria:

(1) Patients with severe cardiac, pulmonary or coagulation dysfunction, multiple bone metastases or other distant metastases; (2) Patients with severe preoperative bladder dysfunction; (3) Patients with a history of previous pelvic surgery and pelvic radiotherapy; (4) Patients with communication impairment; (5) Other conditions that the investigators consider inappropriate to participate in the study.

研究实施时间:

Study execute time:

From 2023-01-01 00:00:00 To 2024-06-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2023-01-01 00:00:00 To 2023-06-01 00:00:00

干预措施:

Interventions:

组别:

盆底肌训练组

样本量:

100

Group:

PFMT group

Sample size:

干预措施:

盆底肌训练

干预措施代码:

Intervention:

PFMT

Intervention code:

组别:

对照组

样本量:

100

Group:

control group

Sample size:

干预措施:

干预措施代码:

Intervention:

none

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中华人民共和国

省(直辖市):

浙江省 

市(区县):

 

Country:

China

Province:

Zhejiang

City:

单位(医院):

浙江大学医学院附属邵逸夫医院 

单位级别:

三甲 

Institution
hospital:

Sir Run Run Shaw Hospital

Level of the institution:

grade A tertiary hospital

测量指标:

Outcomes:

指标中文名:

尿垫数量

指标类型:

主要指标

Outcome:

the number of pads

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

尿道膜部长度

指标类型:

主要指标

Outcome:

MUL

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

超声观察下膀胱尿道结合处位移

指标类型:

主要指标

Outcome:

UVJ displacement

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

超声观察下尿道中段背侧位移

指标类型:

主要指标

Outcome:

MU displacement

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

超声观察下直肠肛管结合处位移

指标类型:

主要指标

Outcome:

ABJ displacement

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

超声观察下阴茎球部位移

指标类型:

主要指标

Outcome:

BC displacement

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

国际前列腺症状评分

指标类型:

主要指标

Outcome:

IPSS

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

阴茎背神经躯体感觉诱发的电位

指标类型:

主要指标

Outcome:

Dorsal penile nerve SEP

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

阴部神经躯体感觉诱发的电位

指标类型:

主要指标

Outcome:

pudendal nerve SEP

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

球海绵体反射

指标类型:

主要指标

Outcome:

BCR

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

阴部交感神经皮肤反应

指标类型:

主要指标

Outcome:

Perineal SSR

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

盆底肌电图

指标类型:

主要指标

Outcome:

Pelvic Floor EMG

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age years
最大 Max age years

性别:

男性

Gender:

Male

随机方法(请说明由何人用什么方法产生随机序列):

按照就诊顺序随机分到对照组或干预组

Randomization Procedure (please state who generates the random number sequence and by what method):

Patients are randomly assigned to the control or intervention group according to the order of consultation

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

未说明

Blinding:

Not stated

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

随访结束6个月后,数据上传

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

6 months after the end of the follow-up.Data upload.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

CRF病例记录表,临床试验公共管理平台

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form,Clinical Trial Management Public Platform

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2022-12-21 16:31:59